Zacks downgrades Haleon stock from Hold to Strong Sell

Published on 10/25/2026 at 12:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Zacks moved Haleon from Hold to Strong Sell on October 22, 2026. Haleon stock closed at EUR 4.57 on October 23, 2026, ahead of October 29 results.

Ratings and operating figures

Zacks moved Haleon from Hold to Strong Sell in a report issued on October 22, 2026.
First-half 2026 revenue reached GBP 5.60 billion, up 2.20 percent from the prior year.
Haleon stock closed at EUR 4.57 on October 23, 2026.

Architektur-Render eines Glasbürogebäudes mit begrüntem Vorplatz und Menschen — Haleon plc (ISIN GB00BMX86B70) repräsentiert ein globales Konsumgüterunternehmen mit modernen Bürostandorten für Gesundheitsprodukte, Illustration mit AI erstellt.

Haleon plc (ISIN GB00BMX86B70) faced a fresh analyst downgrade as Zacks Research moved its rating from Hold to Strong Sell in a report issued on October 22, 2026, according to MarketBeat. The rating change arrives before Haleon's next scheduled trading update.

Why the downgrade matters

The latest analyst move contrasts with Haleon's operating profile. First-half 2026 revenue rose 2.20 percent to GBP 5.60 billion, while net income fell 5.50 percent to GBP 762.0 million, according to Simply Wall St. Profit margin declined to 14.00 percent from 15.00 percent in the first half of 2025, putting execution and cost control at the center of the investment case.

The rating split is material because MarketBeat also cited an average analyst price target of USD 4.90 for Haleon's American depositary receipt, while the same report described the broader consensus as Moderate Buy. That contrast leaves the next operating update important for testing whether revenue growth can translate into stronger earnings.

Three dated Haleon events

Haleon announced the Excedrin Rapid Relief launch and its My Little Headache digital campaign on October 13, 2026, with relief beginning in as little as 15 minutes, as reported by Simply Wall St. On July 31, 2026, first-half results showed GBP 5.60 billion of revenue and GBP 762.0 million of net income. The October 22, 2026 Zacks downgrade was the latest of the three events.

What comes next for Haleon

Haleon lists its Q3 2026 trading statement for October 29, 2026, on its investor relations page. The company also outlines a GBP 800 million gross savings plan over five years and maintains a long-term goal of 4.00 to 6.00 percent annual organic revenue growth. Those figures give investors a clear test: the upcoming statement must show whether productivity gains are offsetting slower profit conversion.

The stock's latest close

Haleon stock last closed at EUR 4.57 on Xetra on October 23, 2026. The London listing uses ticker HLN, and the company operates in consumer healthcare across oral care, pain relief, respiratory health, vitamins and supplements.

Haleon stock closed at EUR 4.57 on October 23, 2026.